Revolutionary Approaches to Improving Outcomes in Unresected LA SCCHN
Are you and your team incorporating the latest data on unresected locally advanced squamous cell carcinoma of the head and neck into practice?
Join our international multidisciplinary panel of experts in exploring revolutionary approaches to treating patients with unresectable locally advanced squamous cell carcinoma of the head and neck and dinner. Through engaging presentations and discussions, the panel will address key aspects of patient management including new and emerging therapies, the clinical significance of early endpoints used in clinical trials, and future directions in treatment.
Times listed in Pacific Daylight Time
6:15pm – 6:30pm Doors Open, Registration, and Dinner
6:30pm – 6:33pm Welcome and Introductions
6:33pm – 6:37pm Overview of LA SCCHN
6:37pm – 6:47pm Current Landscape in LA SCCHN
6:47pm – 6:59pm Raising Awareness of Emerging Evidence in LA SCCHN
6:59pm – 7:11pm A Comprehensive Analysis of IAPs
7:11pm – 7:20pm Understanding Clinical Trials and Their Endpoints in LA SCCHN
7:20pm – 7:30pm Question and Answer Session
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Ezra Cohen, MD, FRCPSC, FASCO
Chief Medical Officer, Oncology
Tempus Labs
Professor of Medicine, Division of Hematology/Oncology
University of California San Diego Health
San Diego, CA, US
Consulting Fees: Adagene, Astellas, Cidara, Eisai, Genmab, Gilboa, iTeos, Lilly, MSD, Merck, Nectin Tx, Novartis, Nykode, Pangea Therapeutics, PCI Biotech, Replimune, Roche, Soteria, Tempus, Viracta
Employee of an ineligible company: Tempus Labs
Ownership Interest: Kinnate Biopharma, Primmune Therapeutics
Research: NCI
Faculty:
Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Professor in Biological Cancer Therapies
The Institute of Cancer Research
London UK
Consulting Fees: AstraZeneca, Boehringer Ingelheim, Merck, MSD, Replimune
Research: AstraZeneca, Boehringer Ingelheim, Replimune
Deborah J. Wong, MD, PhD
Associate Clinical Professor of Medicine
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA, US
Consulting Fees: MSD
Research: AstraZeneca, BICARA Therapeutics, Bristol-Myers Squibb Company, FSTAR Therapeutics, Genentech, Gilead, KURA Oncology, Lilly, MSD, Pfizer, Regeneron, TopAlliance
Reviewers/Content Planners/Authors:
After participating in this educational activity, participants should be better able to:
This activity is designed to meet the educational needs of medical oncologists, radiation oncologists, pathologists, and other healthcare professional treating patients with head and neck cancers in the United States.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
This activity is supported by an independent educational grant from EMD Serono, Inc. EMD Serono, Inc. is the Healthcare business of Merck KGaA, Darmstadt, Germany.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
Join our international multidisciplinary panel of experts in exploring revolutionary approaches to treating patients with unresectable locally advanced squamous cell carcinoma of the head and neck and dinner. Through engaging presentations and discussions, the panel will address key aspects of patient management including new and emerging therapies, the clinical significance of early endpoints used in clinical trials, and future directions in treatment.
Times listed in Pacific Daylight Time
6:15pm – 6:30pm Doors Open, Registration, and Dinner
6:30pm – 6:33pm Welcome and Introductions
6:33pm – 6:37pm Overview of LA SCCHN
6:37pm – 6:47pm Current Landscape in LA SCCHN
6:47pm – 6:59pm Raising Awareness of Emerging Evidence in LA SCCHN
6:59pm – 7:11pm A Comprehensive Analysis of IAPs
7:11pm – 7:20pm Understanding Clinical Trials and Their Endpoints in LA SCCHN
7:20pm – 7:30pm Question and Answer Session
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Ezra Cohen, MD, FRCPSC, FASCO
Chief Medical Officer, Oncology
Tempus Labs
Professor of Medicine, Division of Hematology/Oncology
University of California San Diego Health
San Diego, CA, US
Consulting Fees: Adagene, Astellas, Cidara, Eisai, Genmab, Gilboa, iTeos, Lilly, MSD, Merck, Nectin Tx, Novartis, Nykode, Pangea Therapeutics, PCI Biotech, Replimune, Roche, Soteria, Tempus, Viracta
Employee of an ineligible company: Tempus Labs
Ownership Interest: Kinnate Biopharma, Primmune Therapeutics
Research: NCI
Faculty:
Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Professor in Biological Cancer Therapies
The Institute of Cancer Research
London UK
Consulting Fees: AstraZeneca, Boehringer Ingelheim, Merck, MSD, Replimune
Research: AstraZeneca, Boehringer Ingelheim, Replimune
Deborah J. Wong, MD, PhD
Associate Clinical Professor of Medicine
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA, US
Consulting Fees: MSD
Research: AstraZeneca, BICARA Therapeutics, Bristol-Myers Squibb Company, FSTAR Therapeutics, Genentech, Gilead, KURA Oncology, Lilly, MSD, Pfizer, Regeneron, TopAlliance
Reviewers/Content Planners/Authors:
After participating in this educational activity, participants should be better able to:
This activity is designed to meet the educational needs of medical oncologists, radiation oncologists, pathologists, and other healthcare professional treating patients with head and neck cancers in the United States.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
This activity is supported by an independent educational grant from EMD Serono, Inc. EMD Serono, Inc. is the Healthcare business of Merck KGaA, Darmstadt, Germany.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
Pediatric Narcolepsy: A Primer for Clinicians Who Manage Children
Pediatric Narcolepsy: A Primer for Clinicians Who Manage Children
Pediatric Narcolepsy: A Primer for Clinicians Who Manage Children
1.00 program credit
Funke Afolabi-Brown, MD
Pediatric Narcolepsy: Physical Comorbidities
Pediatric Narcolepsy: Physical Comorbidities
Pediatric Narcolepsy: Physical Comorbidities
1.00 program creditKiran Maski, MD, MPH
Evolving Therapy for Managing Pediatric Narcolepsy: Once-Nightly Sodium Oxybate
Evolving Therapy for Managing Pediatric Narcolepsy: Once-Nightly Sodium Oxybate
Evolving Therapy for Managing Pediatric Narcolepsy: Once-Nightly Sodium Oxybate
1.00 program creditAnne Marie Morse, DO
Evolving Therapy for Managing Pediatric Narcolepsy: Wake-Promoting Pitolisant
Evolving Therapy for Managing Pediatric Narcolepsy: Wake-Promoting Pitolisant
Evolving Therapy for Managing Pediatric Narcolepsy: Wake-Promoting Pitolisant
1.00 program creditFunke Afolabi-Brown, MD
We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?
Facebook Comments